Maral Barzegar-Amini1, Hamideh Ghazizadeh2, Seyed Mohammad Reza Seyedi3, Hamid Reza Sadeghnia4, Akram Mohammadi5, Mahdi Hassanzade-Daloee6, Elham Barati2, Sara Kharazmi-Khorassani7, Jasmin Kharazmi-Khorassani8, Maryam Mohammadi-Bajgiran2, Shima Tavallaie2, Gordon A Ferns9, Mohsen Mouhebati10, Mahmoud Ebrahimi10, Maryam Tayefi11, Majid Ghayour-Mobarhan12. 1. Cardiovascular Division, Vascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Department of Biology, Ferdowsi University of Mashhad, Faculty of Sciences, Mashhad, Iran. 4. Department of Pharmacology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 6. Cardiovascular Division, Vascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 7. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Biology, Mashad Branch, Islamic Azad University, Iran. 8. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Chemistry, Mashad Branch, Ferdowsi University, Iran. 9. Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex, BN1 9PH, UK. 10. Cardiovascular Division, Vascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Cardiovascular Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 11. Clinical Research Unit, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: tayefi.maryam@gmail.com. 12. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: ghayourm@mums.ac.ir.
Abstract
OBJECTIVES: Obesity and overweight are among the main causes of cardiovascular disease (CVD) mortality. Dyslipidemia, fatty liver index, is strongly related to CVD. Vitamin E as an antioxidant protects the hepatic cells against oxidative stress and prevents fatty liver disease. The aim of the current study is to evaluate the relationship between anthropometric parameters and fasted lipid profile with serum vitamin E levels. STUDY DESIGN: A randomized trial was designed based on data from the Mashhad stroke and heart atherosclerotic disorders (MASHAD: 2010-2020). METHODS: 363 CVD subjects (173 males and 190 females) was selected at random, among 9704 subjects in three regions of Mashhad, northeast of Iran to investigate the specific correlations among their serum vitamin E, lipid profile (TG, HDL-C, LDL-C and TC), and anthropometric features (height, weight, BMI, hip and waist circumferences. RESULT: The results indicated the significant relationships between vitamin E, and fasting serum lipid profile in subjects. Serum vitamin E was negatively correlated to TC, TG, and LDL-C and positively related to HDL-C. Also, statistically negative correlations were found between vitamin E and anthropometric parameters (weight, waist and hip circumference, middle Arm, and Systolic Blood Pressure). Moreover, vitamin E ratios such as vitamin E/(TC + TG) and vitamin E/TC values as standardized vitamin E, had significant negative correlation with BMI, the whole of anthropometric parameters, and dyslipidemia risk factors including TC, TG and LDL-C. CONCLUSION: We found that vitamin E profile was significantly lower in the dyslipidemia subjects. It is generally suggested that vitamin E monitoring might be used as a useful prognostic and therapeutic agent in dyslipidemia disorder.
OBJECTIVES: Obesity and overweight are among the main causes of cardiovascular disease (CVD) mortality. Dyslipidemia, fatty liver index, is strongly related to CVD. Vitamin E as an antioxidant protects the hepatic cells against oxidative stress and prevents fatty liver disease. The aim of the current study is to evaluate the relationship between anthropometric parameters and fasted lipid profile with serum vitamin E levels. STUDY DESIGN: A randomized trial was designed based on data from the Mashhad stroke and heart atherosclerotic disorders (MASHAD: 2010-2020). METHODS: 363 CVD subjects (173 males and 190 females) was selected at random, among 9704 subjects in three regions of Mashhad, northeast of Iran to investigate the specific correlations among their serum vitamin E, lipid profile (TG, HDL-C, LDL-C and TC), and anthropometric features (height, weight, BMI, hip and waist circumferences. RESULT: The results indicated the significant relationships between vitamin E, and fasting serum lipid profile in subjects. Serum vitamin E was negatively correlated to TC, TG, and LDL-C and positively related to HDL-C. Also, statistically negative correlations were found between vitamin E and anthropometric parameters (weight, waist and hip circumference, middle Arm, and Systolic Blood Pressure). Moreover, vitamin E ratios such as vitamin E/(TC + TG) and vitamin E/TC values as standardized vitamin E, had significant negative correlation with BMI, the whole of anthropometric parameters, and dyslipidemia risk factors including TC, TG and LDL-C. CONCLUSION: We found that vitamin E profile was significantly lower in the dyslipidemia subjects. It is generally suggested that vitamin E monitoring might be used as a useful prognostic and therapeutic agent in dyslipidemia disorder.
Authors: Katarzyna Zabłocka-Słowińska; Sylwia Płaczkowska; Katarzyna Skórska; Anna Prescha; Konrad Pawełczyk; Irena Porębska; Monika Kosacka; Halina Grajeta Journal: PLoS One Date: 2019-04-11 Impact factor: 3.240